For example, SGLT2i use leads to a 33% reduction (95% CI 26, 38) in hospitalisation for heart failure (HF) and a 35% reduction (95% CI 19, 47) in the incidence of end-stage kidney disease (ESKD) [3, 4], and GLP-1 RA use leads to a 10% reduction (95% CI 2, 17) in myocardial infarction (MI) and a 17% reduction (95% CI 8, 24) reduction in stroke [2]. The gene discussed is GLP1R; the disease is myocardial infarction.